CN100479819C - Composition comprising itraconazole for oral administration - Google Patents
Composition comprising itraconazole for oral administration Download PDFInfo
- Publication number
- CN100479819C CN100479819C CNB2006100651366A CN200610065136A CN100479819C CN 100479819 C CN100479819 C CN 100479819C CN B2006100651366 A CNB2006100651366 A CN B2006100651366A CN 200610065136 A CN200610065136 A CN 200610065136A CN 100479819 C CN100479819 C CN 100479819C
- Authority
- CN
- China
- Prior art keywords
- itraconazole
- solid dispersion
- orally administered
- administered composition
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 title claims description 79
- 229960004130 itraconazole Drugs 0.000 title claims description 79
- 239000007962 solid dispersion Substances 0.000 claims abstract description 59
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 39
- -1 hydroxypropyl Chemical group 0.000 claims description 22
- 241001597008 Nomeidae Species 0.000 claims description 20
- 238000010521 absorption reaction Methods 0.000 claims description 19
- 239000003623 enhancer Substances 0.000 claims description 18
- 230000008595 infiltration Effects 0.000 claims description 17
- 238000001764 infiltration Methods 0.000 claims description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 11
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 11
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 11
- 238000004132 cross linking Methods 0.000 claims description 9
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 7
- 239000001095 magnesium carbonate Substances 0.000 claims description 7
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 7
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 229940080313 sodium starch Drugs 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 3
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 235000011147 magnesium chloride Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004380 Cholic acid Substances 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- 239000003613 bile acid Substances 0.000 claims description 2
- 235000019416 cholic acid Nutrition 0.000 claims description 2
- 229960002471 cholic acid Drugs 0.000 claims description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 2
- 235000011151 potassium sulphates Nutrition 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims 1
- 125000003716 cholic acid group Chemical group 0.000 claims 1
- 239000000411 inducer Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 21
- 238000004090 dissolution Methods 0.000 description 20
- 239000003826 tablet Substances 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 235000015165 citric acid Nutrition 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 239000008119 colloidal silica Substances 0.000 description 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 10
- 229940068968 polysorbate 80 Drugs 0.000 description 10
- 229920000053 polysorbate 80 Polymers 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 238000007922 dissolution test Methods 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 229920003169 water-soluble polymer Polymers 0.000 description 9
- 239000000454 talc Substances 0.000 description 8
- 235000012222 talc Nutrition 0.000 description 8
- 229910052623 talc Inorganic materials 0.000 description 8
- 230000018044 dehydration Effects 0.000 description 7
- 238000006297 dehydration reaction Methods 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000012530 fluid Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229940063138 sporanox Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000003929 dermatomycosis Diseases 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000019222 white chocolate Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an intake composition with Yiqu-pyrazole, which comprises the following parts: 40-69.9 wt% solid dispersion, 0.1-30 wt% penetrating inducer and 0.1-30 wt% disintegration agent, wherein the solid dispersion is prepared by dispersing 1 wt% Yiqu-pyrazole in the 0.1-10wt% methyl hydroxypropylcellulose to mix with 0.01-5wt% absorbing accelerating agent in the composition at amorphous pattern.
Description
The mutual reference of related application
The application requires the priority of the korean patent application No.10-2005-0022312 that submits on March 17th, 2005, and this description is included in described application by reference mode hereby in, so that it is as complete in this manual proposition.
Invention field
The present invention relates to a kind of Orally administered composition, described compositions contains the solid dispersion of 40～69.9wt% (percentage by weight), the infiltration derivant of 0.1～30wt% and the disintegrating agent (disintegrant) of 0.1～30wt%, wherein, described solid dispersion is dispersed in by the itraconazole with 1 weight portion in the absorption enhancer mixture of the hydroxypropyl emthylcellulose of 0.1～10 weight portion and 0.01～5 weight portion and prepares with amorphism.
Background technology
Itraconazole, be called again (±)-suitable-4-that (((((2-(2 for 4-for 4-for 4-, the 4-Dichlorobenzene base)-2-(1H-1,2,4-triazol-1-yl methyl)-1,3-dioxolanes-4-yl) phenyl methoxyl group))-and the 1-piperazinyl)-2,4-dihydro-2-(1-methyl-propyl)-3H-1,2,4-triazole-3-ketone, having known it is a kind of fungicidal agents with antifungal broad spectrum activity, particularly a kind of safe and effective medicine for the treatment of dermatomycosis.Yet although itraconazole has effective Fungicidally active, it is a kind of insoluble drugs, and its water solublity and pKa value are all lower, is respectively below the 1 μ g/ml with 3.7, so promptly be ionized under very low pH.Therefore, there is the low-down problem of its bioavailability in itraconazole when oral administration.
For the water solublity that improves itraconazole improving its bioavailability, WO 85/002767 and US4,764,604 disclose the clathrate (includedcomplex) of a kind of itraconazole and cyclodextrin, but all fail to improve the water solublity of itraconazole.In addition, US 5,504,105 disclose a kind of oral Pharmaceutical composition, this pharmaceutical composition is characterised in that active component is dispersed in hydrogenated vegetable oil, medium chain triglycerides, white chocolate and the soybean lecithin, but its bioavailability has only improved 1.2～1.8 times at the most, and is very little to the influence of active component effect.
WO 97/44014 discloses a kind of solid dispersion of itraconazole, this solid dispersion has the influence of high bioavailability and unable to take food thing, its preparation is by adopting fusion-extrusion molding with itraconazole with such as mixture heated to 245～265 of water-soluble polymers such as hydroxypropyl emthylcellulose ℃, so that fused itraconazole is dispersed in the unfused water-soluble polymer.Yet wherein have several problems: fusion method should carry out under up to 245～265 ℃ temperature, and fused itraconazole is difficult to be evenly dispersed in the polymer.In addition, unfused itraconazole is in vivo residual, thereby stripping or absorption in vivo had side effects.
Korean Patent communique No.2001-0098419 discloses a kind of method that realizes solid dispersion, be about in the mixture that insoluble itraconazole is dispersed in polyvinylpyrrolidone and a kind of absorption enhancer, thereby the crystal form medicine is made for the amorphism medicine, to significantly improve water solublity.Yet, its problem is that the disintegrate of solid dispersion does not take place for a long time, and the dissolution of itraconazole (dissolution rate) is low, and this is because used excessive polyvinylpyrrolidone, even when in mimic gastric juice, solid preparation being carried out dissolution test, also be like this.
Therefore, needing a kind of insoluble drugs of exploitation is the higher Orally administered composition of bioavailability of itraconazole.
Summary of the invention
The present inventor finds, to permeate derivant, for example potassium chloride, magnesium carbonate etc., and disintegrating agent is when being added in the solid dispersion in the mixture that itraconazole wherein is scattered in hydroxypropyl emthylcellulose and absorption enhancer, the dissolving out capability of insoluble itraconazole can suitably be controlled and be significantly improved, thereby realizes the present invention.
Therefore, the object of the present invention is to provide a kind of Orally administered composition, described Orally administered composition contains solid dispersion, infiltration derivant and disintegrating agent, and wherein said solid dispersion is by preparing with amorphism in the mixture that itraconazole is dispersed in hydroxypropyl emthylcellulose and absorption enhancer.
Another object of the present invention is to provide a kind of preparation to contain the method for the Orally administered composition of itraconazole, the itraconazole of said composition has high bioavailability, described method comprises: itraconazole is dispersed in the mixture of hydroxypropyl emthylcellulose and absorption enhancer to prepare amorphous solid dispersion, then described solid dispersion is mixed mutually with infiltration derivant and disintegrating agent.
Another object of the present invention is to provide a kind of solid dispersion, and this solid dispersion is by in the mixture that itraconazole is dispersed in hydroxypropyl emthylcellulose and absorption enhancer and prepare with amorphism.
Description of drawings
It is the result of 1.2 o'clock dissolution test at pH that Fig. 1 shows the compositions that is made by the embodiment of the invention and Comparative Examples.
●: embodiment 2,
Zero: embodiment 3,
▲: Comparative Examples 1,
△: Comparative Examples 2.
Fig. 2 shows the result of the dissolution test of the compositions that made by the embodiment of the invention 2 and commercial preparation.
●: embodiment 2,
: the commercial preparation (Sporanox of Janssen Korea Ltd.
TMCapsule).
Fig. 3 shows the result of the dissolution test of compositions when pH4.0 and pH6.8 that is made by the embodiment of the invention 2 and Comparative Examples 2.
▲: pH4.0+1% polysorbate80 (Polysorbate 80), the compositions of embodiment 2,
■: the pH4.0+1% polysorbate80, the compositions of Comparative Examples 2,
△: the pH6.8+1% polysorbate80, the compositions of embodiment 2,
: pH6.8+1% polysorbate80, the compositions of Comparative Examples 2.
The result of the dissolution test of solid dispersion (SDH) when pH1.2 and pH4.0 that Fig. 4 shows the solid dispersion (SDP) that contains polyvinylpyrrolidone and contains hydroxypropyl emthylcellulose.
▲：SPD-pH1.2，
△：SDH-pH1.2，
■：SDP-pH4.0，
□：SDH-pH4.0。
The specific embodiment
In conjunction with following detailed description, evaluation and the attendant advantages thereof more complete to the present invention will be more obvious along with the intensification of understanding.
The present invention relates to a kind of Orally administered composition, described compositions contains the solid dispersion of 40～69.9wt%, the infiltration derivant of 0.1～30wt% and the disintegrating agent of 0.1～30wt%, wherein, described solid dispersion is dispersed in by the itraconazole with 1 weight portion in the absorption enhancer mixture of the hydroxypropyl emthylcellulose of 0.1～10 weight portion and 0.01～5 weight portion and prepares with amorphism.
In addition, the invention still further relates to the method that a kind of preparation contains the Orally administered composition of itraconazole, the itraconazole of said composition has high bioavailability, and described method comprises the steps:
The itraconazole of 1 weight portion is dispersed in the absorption enhancer mixture of the hydroxypropyl emthylcellulose of 0.1～10 weight portion and 0.01～5 weight portion preparing amorphous solid dispersion,
The described solid dispersion of 40～69.9wt% is mixed mutually with the infiltration derivant of 0.1～30wt% and the disintegrating agent of 0.1～30wt%.
And, the invention still further relates to a kind of solid dispersion, this solid dispersion is dispersed in by the itraconazole with 1 weight portion in the absorption enhancer mixture of the hydroxypropyl emthylcellulose of 0.1～10 weight portion and 0.01～5 weight portion and prepares with amorphism.
Korean Patent communique No.2001-0098419 discloses a kind of itraconazole preparation, and wherein the bioavailability of this itraconazole preparation is improved by itraconazole is made for amorphism.Yet, there is a problem like this, when itraconazole preparation during with solid dispersion form oral administration, active component, be the stripping meeting time-delay of itraconazole in simulated gastric fluid, this is because used excessive water-soluble polymer polyvinylpyrrolidone when the preparation solid dispersion.
For solving the problem of above-mentioned itraconazole stripping time-delay in gastric environment, in the present invention, water-soluble polymer is adopted in the preparation of itraconazole solid dispersion, it is hydroxypropyl emthylcellulose, and absorption enhancer, citric acid for example, thus in the solution that contains simulated gastric fluid and 1% (w/w) polysorbate80 of pH1.2 and pH4.0, dissolution has been significantly improved more than 20%.And in the present invention, also the solid dispersion to itraconazole adds the infiltration derivant, as potassium chloride, magnesium carbonate etc., and disintegrating agent, as microcrystalline Cellulose, sodium starch glycollate etc., so that the effectively stripping in gastric environment of insoluble itraconazole.
In the present invention, the itraconazole solid dispersion can be dispersed in by the itraconazole with 1 weight portion in the absorption enhancer mixture of the hydroxypropyl emthylcellulose of 0.1～10 weight portion and 0.01～5 weight portion and make with amorphism.The content of itraconazole solid dispersion is preferably 40～69.9wt%, in the gross weight of Orally administered composition.If the content of itraconazole solid dispersion less than 40wt%, will be not enough to obtain required drug effect; And if the content of itraconazole solid dispersion will have side effects to effective stripping of itraconazole greater than 69.9wt%.
In the present invention, absorption enhancer can be selected from one or more in citric acid, ascorbic acid, bile acid, cholic acid, mannitol, salicylic acid, glucose, dextrose, sucrose, sorbitol and the maltose.
In the present invention, the infiltration derivant can be selected from one or more in sodium chloride, potassium chloride, magnesium chloride, potassium sulfate, sodium sulfate, magnesium sulfate, magnesium carbonate, calcium bicarbonate, mannitol, glucose, lactose and the sucrose.The content of infiltration derivant is preferably 0.1～30wt%, in the gross weight of Orally administered composition.If the content of infiltration derivant is less than 0.1wt%, the then itraconazole stripping of will delaying time; If the content of infiltration derivant is greater than 30wt%, then the stripping of itraconazole improves fast, causes side effect, for example skin allergy etc.
In the present invention, disintegrating agent can be selected from one or more in microcrystalline Cellulose, low hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose (croscamellose sodium), sodium starch glycollate, sodium carboxymethyl cellulose, carboxymethyl cellulose and the crospolyvinylpyrrolidone (crospovidone) that replaces.The content of disintegrating agent is preferably 0.1～30wt%, in the gross weight of Orally administered composition.If the content of disintegrating agent is less than 0.1wt%, disintegrate will be delayed time; If the content of disintegrating agent is greater than 30wt%, solid preparation will to have flowability and compressibility difference etc. former thereby be difficult to preparation owing to granule.
In addition, Orally administered composition of the present invention also can comprise and is selected from pharmaceutically acceptable excipient, binding agent and the lubricant one or more.
In the present invention, excipient can be selected from one or more in lactose, white sugar, glucose, fructose, mannitol, corn starch, potato starch, wheaten starch, pre-gelatinized starch, microcrystalline Cellulose or cellulose derivative, dextrin, calcium hydrogen phosphate, dalcium biphosphate, calcium carbonate, polacrilin potassium, acetic acid, ammonium carbonate, ammonium phosphate, boric acid, lactic acid, citric acid, potassium phosphate, sodium phosphate, sodium acetate, sodium citrate, sodium lactate, ascorbic acid and the ascorbic palmitate.The content of excipient is preferably 2～90wt%, in the gross weight of Orally administered composition.
In the present invention, binding agent can be selected from one or more in hydroxypropyl cellulose, hydroxypropyl emthylcellulose, hydroxylated cellulose, methylcellulose, ethyl cellulose, hydroxyethyl-cellulose, polyvinylpyrrolidone, polyvinyl alcohol, gelatin, dextrin and the microcrystalline Cellulose.The content of binding agent is preferably 2～40wt%, in the gross weight of Orally administered composition.
In the present invention, lubricant can be selected from one or more in magnesium stearate, sodium stearyl fumarate, stearic acid, Talcum, silicon dioxide and the colloidal silica.The content of lubricant is preferably 0.1～20wt%, in the gross weight of Orally administered composition.
Orally administered composition of the present invention can preferably be made the solid that is used for oral administration, for example tablet, capsule, granule, powder, pill, dry syrup or the like, preferred tablet or capsule.
Orally administered composition of the present invention can be made into and contains 100～400mg, the unit dosage forms of preferred 150～300mg itraconazole solid dispersion.Dosage unit is preferably tablet or capsular form.In one week of administration, Orally administered composition of the present invention is administered twice preferred every day, each 200mg itraconazole.
As shown in Figure 4, use the itraconazole solid dispersion of water-soluble polymer hydroxypropyl emthylcellulose and absorption enhancer citric acid preparation to show higher dissolution in the solution of pH1.2 that contains simulated gastric fluid and 1% (w/w) polysorbate80 and pH4.0, this speed is than dissolution height at least 20% disclosed according to Korean Patent communique No.2001-0098419, that adopt the itraconazole solid dispersion of water-soluble polymer polyvinylpyrrolidone preparation.And, Orally administered composition of the present invention except that contain the itraconazole solid dispersion external, also contain the infiltration derivant, for example potassium chloride, magnesium carbonate etc., and disintegrating agent, for example microcrystalline Cellulose, sodium starch glycollate etc., thus show the effective stripping of insoluble itraconazole in gastric environment.
Further the present invention will be described in more detail in conjunction with following embodiment.These embodiment only are intended to the present invention exemplarily is described, and should not be construed as by any way the scope of the invention are limited.
Embodiment 1
One hectogram raw material itraconazole preparation (Sigma Chemical) is dissolved in 1, in the 000g dichloromethane.Then, 22.2g fully is dissolved in 2 as the citric acid and the 100g hydroxypropyl emthylcellulose (Dow Chemical, weight average molecular weight is 10,000～1,500,000) of absorption enhancer, (1:1 is v/v) in the mixed solvent for 000g dichloromethane/ethanol.Adopt spray dryer (B-191 mini spray exsiccator, Buchi Co., Switzerland) mixture solution of itraconazole solution and hydroxypropyl emthylcellulose and citric acid is sprayed, be scattered in solid dispersion in hydroxypropyl emthylcellulose and the citric acid to form itraconazole, generate white amorphous powder.Itraconazole: hydroxypropyl emthylcellulose: the weight ratio of citric acid is 45:45:10.
Embodiment 2
The itraconazole solid dispersion that embodiment 1 is made also fully mixes by the screening of 30 purpose mesh screens with colloidal silica.Then, other component in wherein adding tabulation 1 down except that magnesium stearate and Talcum is mixed, and dry and pelletize is crossed 25 order mesh screens and obtained the size homogeneous granules.Subsequently, to wherein adding magnesium stearate and Talcum and fully mixing, mixture is made tablet.120g Opadry AMB (Opadry AMB) (Colorcon) is added in the 546g pure water, fully mix with the preparation coating solution.Adopt tablet coating machine (the automatic coating machine of SFC-30FN type, Sejong Pharmatech, Korea S), keeping inlet temperature is 60～70 ℃, outlet temperature is 40～43 ℃, and coating solution is filmed on the tablet that makes, and wherein every tablet scribbles the coating solution of 20mg.
[table 1]
| The itraconazole solid dispersion | 222.2mg |
| Microcrystalline Cellulose | 58.0mg |
| The dehydration lactose | 143.0mg |
| Cross-linking sodium carboxymethyl cellulose | 120.0mg |
| Magnesium carbonate | 20.0mg |
| Colloidal silica | 8.0mg |
| Talcum | 7.0mg |
| Magnesium stearate | 6.0mg |
Embodiment 3
Component in itraconazole solid dispersion that employing embodiment 1 makes and the following tabulation 2 prepares tablet.Adopt and prepare tablet and it is carried out coating as method identical among the embodiment 2.
[table 2]
| The itraconazole solid dispersion | 222.2mg |
| Microcrystalline Cellulose | 58.0mg |
| The dehydration lactose | 153.0mg |
| Cross-linking sodium carboxymethyl cellulose | 120.0mg |
| Magnesium carbonate | 10.0mg |
| Colloidal silica | 8.0mg |
| Talcum | 7.0mg |
| Magnesium stearate | 6.0mg |
Embodiment 4
Component in itraconazole solid dispersion that employing embodiment 1 makes and the following tabulation 3 prepares tablet.Adopt and prepare tablet and it is carried out coating as method identical among the embodiment 2.
[table 3]
| The itraconazole solid dispersion | 222.2mg |
| Microcrystalline Cellulose | 83.0mg |
| The dehydration lactose | 123.0mg |
| Cross-linking sodium carboxymethyl cellulose | 115.0mg |
| Magnesium chloride | 20.0mg |
| Colloidal silica | 8.0mg |
| Talcum | 7.0mg |
| Magnesium stearate | 6.0mg |
Embodiment 5
Itraconazole solid dispersion and colloidal silica that embodiment 1 is made sieve by 30 order mesh screens, and fully mix.Then, other component in wherein adding tabulation 4 down except that magnesium stearate is mixed, and dry and pelletize is crossed 25 order mesh screens and obtained the size homogeneous granules.Subsequently, to wherein adding magnesium stearate and fully mixing with the preparation tablet.After tablet forms, by tablet being carried out coating as method identical among the embodiment 2.
[table 4]
| The itraconazole solid dispersion | 222.2mg |
| Microcrystalline Cellulose | 80.0mg |
| The dehydration lactose | 173.0mg |
| Cross-linking sodium carboxymethyl cellulose | 75.0mg |
| Potassium chloride | 20.0mg |
| Colloidal silica | 8.0mg |
| Magnesium stearate | 6.0mg |
Embodiment 6
Component in itraconazole solid dispersion that employing embodiment 1 makes and the following tabulation 5 prepares tablet.Adopt and prepare tablet and it is carried out coating as method identical among the embodiment 2.
[table 5]
| The itraconazole solid dispersion | 222.2mg |
| Microcrystalline Cellulose | 70.0mg |
| The dehydration lactose | 133.0mg |
| Cross-linking sodium carboxymethyl cellulose | 135.0mg |
| Calcium bicarbonate | 10.0mg |
| Colloidal silica | 8.0mg |
| Magnesium stearate | 6.0mg |
Comparative Examples 1
Component in itraconazole solid dispersion that employing embodiment 1 makes and the following tabulation 6 prepares tablet.Adopt and prepare tablet and it is carried out coating as method identical among the embodiment 2.
[table 6]
| The itraconazole solid dispersion | 222.2mg |
| Microcrystalline Cellulose | 93.0mg |
| The dehydration lactose | 158.0mg |
| Cross-linking sodium carboxymethyl cellulose | 90.0mg |
| Colloidal silica | 8.0mg |
| Talcum | 7.0mg |
| Magnesium stearate | 6.0mg |
Comparative Examples 2
Component in itraconazole solid dispersion that employing embodiment 1 makes and the following tabulation 7 prepares tablet.Adopt and prepare tablet and it is carried out coating as method identical among the embodiment 2.
[table 7]
| The itraconazole solid dispersion | 222.2mg |
| Microcrystalline Cellulose | 78.0mg |
| The dehydration lactose | 143.0mg |
| Cross-linking sodium carboxymethyl cellulose | 120.0mg |
| Colloidal silica | 8.0mg |
| Talcum | 7.0mg |
| Magnesium stearate | 6.0mg |
Comparative Examples 3
One hectogram raw material itraconazole preparation (Sigma Chemical) is dissolved in 1, in the 000g dichloromethane.Then, 22.2g fully is dissolved in 2 as the citric acid and the 200g polyvinylpyrrolidone (BASF, weight average molecular weight is 2,500～3,000,000) of absorption enhancer, (1:1 is v/v) in the mixed solvent for 000g dichloromethane/ethanol.Adopt spray dryer (B-191 mini spray exsiccator, Buchi Co., Switzerland) mixture solution of itraconazole solution and polyvinylpyrrolidone and citric acid is sprayed, be scattered in solid dispersion in polyvinylpyrrolidone and the citric acid to form itraconazole, generate white amorphous powder.Itraconazole: polyvinylpyrrolidone: the weight ratio of citric acid is 45:45:10.
Experimental example 1: dissolution test
Compositions and commercial preparation (Janssen Korea Ltd.Sporanox that embodiment 2～6 and Comparative Examples 1～2 are made
TMCapsule) carries out dissolution test.The results are shown in down among tabulation 8 and Fig. 1 and 2.The solution (Korean Pharmacopeia) of pH1.2 as dissolution fluid, and is determined dissolution by the stripping quantity of the itraconazole that recorded by efficient liquid phase chromatographic analysis (HPLC).In this manual, dissolution is all measured according to above-mentioned identical mode.
[table 8]
As table 8 and shown in Figure 1, contain disintegrating agent in Comparative Examples 1 and 2 but do not contain in the compositions of permeating derivant, dissolution is significantly lower, and is difficult to control, because the slight change of each constituent content will cause the remarkable change of dissolution.And contain in the compositions of infiltration derivant and disintegrating agent at embodiment 2～6, dissolution significantly improves, and can (referring to Fig. 1) control dissolution in wide region.
In addition, as table 8 and shown in Figure 2, the compositions of the embodiment of the invention 2 also shows the dissolution equal or higher with the commercial preparation.
And below the experiment of carrying out will show that the present invention contains the compositions of permeating derivant and all have higher dissolution under pH4.0 and pH6.8 and pH1.2.Measure the dissolution that embodiment 2 (containing infiltration derivant and disintegrating agent) and Comparative Examples 2 contain (not containing the infiltration derivant) compositions of itraconazole respectively in the solution that contains 1% polysorbate80 of pH4.0 and in the solution that contains 1% polysorbate80 of pH6.8.The results are shown in Fig. 3.As shown in Figure 3, the present invention contains the compositions of infiltration derivant and disintegrating agent, and its dissolution all is higher than the compositions of Comparative Examples under pH4.0 and pH6.8.
In addition, for the kind of check water-soluble polymer to the influence of dissolution, respectively embodiment 1 is contained hydroxypropyl emthylcellulose and contains polyvinylpyrrolidone as the solid dispersion of water-soluble polymer and Comparative Examples 3 and carry out dissolution test as the solid dispersion of water-soluble polymer.Fill No. 0 capsule with the various solid dispersion of 222.2mg (corresponding to the 100g itraconazole), and in the solution that contains 1% (w/w) polysorbate80 of pH1.2 and pH4.0, each solid dispersion is carried out dissolution test respectively.The results are shown in following table 9 and Fig. 4.
[table 9]
As table 9 and shown in Figure 4, compare with the dissolution that Comparative Examples 3 contains in the solid dispersion of polyvinylpyrrolidone, contain in the solid dispersion of hydroxypropyl emthylcellulose at embodiment 1, dissolution improves at least 20% in the solution of pH1.2, and improves at least 60% in the solution of pH4.0.
As previously mentioned, in Orally administered composition of the present invention, can effectively control and significantly improve the dissolution in gastric environment, thereby solve the low problem of the insoluble bioavailability that causes by itraconazole.And Orally administered composition of the present invention also has economic benefit, because can directly prepare tablet by dry granulation by it.
Claims (4)
1. Orally administered composition, contain:
The solid dispersion of 40～69.9wt% wherein is dispersed in the itraconazole of 1 weight portion in the absorption enhancer of the hydroxypropyl emthylcellulose of 0.1～10 weight portion and 0.01～5 weight portion;
The infiltration derivant of 1～30wt%; And
The disintegrating agent of 1～30wt%,
Wherein said infiltration derivant is selected from one or more in sodium chloride, potassium chloride, magnesium chloride, potassium sulfate, sodium sulfate, magnesium sulfate, magnesium carbonate and the calcium bicarbonate, and described absorption enhancer is selected from citric acid, ascorbic acid, bile acid, mannitol, salicylic acid, glucose, dextrose, sucrose, sorbitol and maltose.
2. the Orally administered composition of claim 1, wherein said absorption enhancer is a cholic acid.
3. the Orally administered composition of claim 1, wherein said disintegrating agent are selected from one or more in microcrystalline Cellulose, low hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose, sodium starch glycollate, sodium carboxymethyl cellulose, carboxymethylcellulose calcium and the crospolyvinylpyrrolidone that replaces.
4. the Orally administered composition of claim 1 further comprises in binding agent and the lubricant one or more.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050022312A KR100555794B1 (en) | 2005-03-17 | 2005-03-17 | Composition comprising itraconazole for oral administration |
| KR1020050022312 | 2005-03-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1853634A CN1853634A (en) | 2006-11-01 |
| CN100479819C true CN100479819C (en) | 2009-04-22 |
Family
ID=37179259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100651366A Expired - Fee Related CN100479819C (en) | 2005-03-17 | 2006-03-17 | Composition comprising itraconazole for oral administration |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR100555794B1 (en) |
| CN (1) | CN100479819C (en) |
| HK (1) | HK1098059A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101780046B (en) * | 2009-01-16 | 2011-09-21 | 北京化工大学 | Itraconazole composite powder and preparation method thereof |
| CN102309488A (en) * | 2010-07-02 | 2012-01-11 | 北京京卫燕康药物研究所有限公司 | Itraconazole medicinal composition and preparation method thereof |
| CN104055747A (en) * | 2013-03-22 | 2014-09-24 | 四川滇虹医药开发有限公司 | Itraconazole pharmaceutical composition, preparation method and application thereof |
| CN112641756B (en) * | 2020-12-29 | 2022-08-19 | 卓和药业集团股份有限公司 | Posaconazole enteric-coated pellet and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1398184A (en) * | 1999-12-08 | 2003-02-19 | 东亚制药株式会社 | Compsns. contg. itraconazole with improved bioavailability and narrow intra-and inter-individual variation of its absorption |
-
2005
- 2005-03-17 KR KR1020050022312A patent/KR100555794B1/en not_active IP Right Cessation
-
2006
- 2006-03-17 CN CNB2006100651366A patent/CN100479819C/en not_active Expired - Fee Related
-
2007
- 2007-04-26 HK HK07104478A patent/HK1098059A1/en not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1398184A (en) * | 1999-12-08 | 2003-02-19 | 东亚制药株式会社 | Compsns. contg. itraconazole with improved bioavailability and narrow intra-and inter-individual variation of its absorption |
Non-Patent Citations (1)
| Title |
|---|
| KR20010098419A（WPI摘要号：2002－251928【30】） 2001.11.08 |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1098059A1 (en) | 2007-07-13 |
| CN1853634A (en) | 2006-11-01 |
| KR100555794B1 (en) | 2006-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014233850B2 (en) | Tofacitinib oral sustained release dosage forms | |
| EP2663310B1 (en) | Oral dosage forms for modified release comprising tasocitinib | |
| NO176203B (en) | Process for the preparation of delayed-release ibuprofen tablets | |
| KR20000062327A (en) | Immediately Disintegrable Medicinal Compositions | |
| KR20100012867A (en) | Solid dosage forms comprising tadalafil | |
| KR100678421B1 (en) | Controlled-release formulation containing tamsulosin hydrochloride | |
| KR101977785B1 (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof | |
| EP4076402A1 (en) | Dosage form comprising amorphous solid solution of empagliflozin with polymer | |
| CN109152787A (en) | Oral preparation with superior stripping property | |
| CN109996542A (en) | Oral disnitegration tablet comprising diamine derivative | |
| KR100791844B1 (en) | Sustained release formulations containing metformin or its salt and processes for preparing the same | |
| EP1847257A2 (en) | Solid preparation comprising enteric solid dispersion | |
| JP2002326927A (en) | Quick-releasing tablet containing metformin hydrochloride | |
| CN100479819C (en) | Composition comprising itraconazole for oral administration | |
| JP2020518611A (en) | Compositions with improved water solubility and bioavailability | |
| WO2011039686A1 (en) | Latrepirdine oral sustained release dosage forms | |
| JP2022544167A (en) | Pharmaceutical composition containing nitroxoline, nitroxoline oral solid tablet, method of preparation thereof, and use thereof | |
| HU221590B (en) | Retarded-action microtablet made of beta-phenylpropiophenone derivatives | |
| CN105431140B (en) | Compound formulation containing slow release of metformin and quick-release HMG-CoA reductase inhibitor | |
| Parikh et al. | Formulation optimization and evaluation of immediate release tablet of telmisartan | |
| CN112168796B (en) | Controlled-release drug sustained-release preparation of biphasic sustained-release system and preparation method thereof | |
| KR102389339B1 (en) | Controlled release high-dose tamsulosin hydrochloride tablet and its preparing method | |
| KR101043816B1 (en) | Controlled release formulation for oral administration of metformin and method | |
| CN114831952A (en) | Isosorbide mononitrate osmotic pump controlled release tablet and preparation method thereof | |
| CN105407875A (en) | Stable pharmaceutical composition in form of coated tablet comprising granules of isoniazid and granules of rifapentine against tuberculosis and process for preparing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1098059 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1098059 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090422 Termination date: 20120317 |